TherapeuticsMD Inc (NASDAQ:TXMD)‘s stock had its “buy” rating reissued by research analysts at Guggenheim in a research report issued to clients and investors on Tuesday.

Other research analysts also recently issued research reports about the company. Oppenheimer Holdings Inc. began coverage on TherapeuticsMD in a report on Tuesday, November 22nd. They set an “outperform” rating and a $12.00 target price on the stock. Zacks Investment Research raised TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Thursday, November 24th. Finally, Jefferies Group initiated coverage on TherapeuticsMD in a report on Tuesday, November 22nd. They issued a “buy” rating and a $18.00 price target on the stock.

TherapeuticsMD (NASDAQ:TXMD) traded up 3.48% during mid-day trading on Tuesday, reaching $5.94. The company’s stock had a trading volume of 4,500,088 shares. The firm’s 50 day moving average price is $6.24 and its 200 day moving average price is $7.31. The firm’s market capitalization is $1.17 billion. TherapeuticsMD has a 52 week low of $4.39 and a 52 week high of $11.26.

COPYRIGHT VIOLATION WARNING: This piece of content was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/30/therapeuticsmd-inc-txmd-given-buy-rating-at-guggenheim.html.

Several hedge funds have recently made changes to their positions in TXMD. Price T Rowe Associates Inc. MD increased its stake in shares of TherapeuticsMD by 8.3% in the third quarter. Price T Rowe Associates Inc. MD now owns 23,465,462 shares of the company’s stock valued at $159,800,000 after buying an additional 1,798,290 shares during the period. BlackRock Fund Advisors increased its stake in shares of TherapeuticsMD by 9.2% in the third quarter. BlackRock Fund Advisors now owns 5,059,418 shares of the company’s stock valued at $34,455,000 after buying an additional 426,991 shares during the period. BlackRock Institutional Trust Company N.A. increased its stake in shares of TherapeuticsMD by 8.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 4,005,977 shares of the company’s stock valued at $27,281,000 after buying an additional 308,027 shares during the period. Rock Springs Capital Management LP increased its stake in shares of TherapeuticsMD by 14.3% in the third quarter. Rock Springs Capital Management LP now owns 1,800,000 shares of the company’s stock valued at $12,258,000 after buying an additional 225,000 shares during the period. Finally, Northern Trust Corp increased its stake in shares of TherapeuticsMD by 0.6% in the third quarter. Northern Trust Corp now owns 1,745,816 shares of the company’s stock valued at $11,888,000 after buying an additional 9,720 shares during the period.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.

5 Day Chart for NASDAQ:TXMD

Receive News & Stock Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related stocks with our FREE daily email newsletter.